Evidence map›Paper›PMID 34149992›Full record

ReviewAmerican journal of translational research2021

Stem cell transplantation for treating liver diseases: progress and remaining challenges.

Shanshan Li, Yanzhen Bi, Zhongping Duan, Yongkai Chang, Feng Hong, Yu Chen

Abstract readReview
PubMed Full text at PMC
In one paragraph

Review in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shanshan LiThe Fourth Liver Disease Center, Beijing Youan Hospital, Capital Medical University Beijing 100069, China.
Yanzhen BiDepartment of Infectious Disease, Qingdao Municipal Hospital Qingdao 266011, Shandong, China.
Zhongping DuanThe Fourth Liver Disease Center, Beijing Youan Hospital, Capital Medical University Beijing 100069, China.
Yongkai ChangDepartment of Neurosurgery, Fuxing Hospital, Capital Medical University Beijing 100038, China.
Feng HongInstitute of Liver Diseases, Affiliated Hospital of Jining Medical University Jining 272000, Shandong, China.
Yu ChenThe Fourth Liver Disease Center, Beijing Youan Hospital, Capital Medical University Beijing 100069, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the development of regenerative medicine, various stem cells are increasingly considered for treating liver diseases. Various stem cells have been reported to play an essential role in liver recovery, and studies have verified the preliminary effectiveness and safety of these therapies. Stem cell-based therapies will emerge as an effective treatment strategy for liver diseases. Thus, the research progress and challenges to the related stem cells were reviewed, namely the classification of stem cells, cell culture, transplantation, cell tracing in the body, therapies for various liver diseases.

Indexed as

liver diseasesStem celltherapytransplantation

Identifiers

PMID34149992
PMCPMC8205777

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.